Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. on June 7, 2018. The report discloses a material corporate governance event: the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Utpal Koppikar as Chief Financial Officer, effective June 7, 2018. Mr. Koppikar joins the company from Gilead Sciences, Inc., where he served as VP, Corporate and Operations Finance.
Management Commentary and Compensation
Management has outlined the following compensatory arrangements for Mr. Koppikar:
- Annual Salary: $425,000
- Sign-on Bonus: $100,000
- Performance Bonus: Target of 35% of base salary, contingent on corporate goals
- Equity Grant: 75,000 stock options and 45,000 restricted stock units
The filing states that Mr. Koppikar has no family relationships with current directors or officers and is not a party to any transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Koppikar's appointment and any transition plans for the previous CFO.
- Review the specific corporate goals tied to the 35% performance bonus target.
- Confirm the vesting schedule and exercise terms for the 75,000 stock options and 45,000 RSUs.
- Check subsequent filings for any updates to the company's financial outlook or capital position following this leadership change.